My understanding is that existing inactivated (whole-virus) vaccines perform worse than mRNA-based spike-targeting vaccines when it comes to neutralization. Here's a small study comparing BNT162b2 and Coronavac[1].
> Third, we have not assessed the T cell immunity against the Omicron variant, which correlates with disease severity.
Non-antibody immune response is understudied. I suspect antibodies are just easy to measure, but, unfortunately for my academic record, there’s more to immune responses than just antibodies.
> Fourth, since all Coronavac recipients had an MN titer of <10 against the Omicron variant and the GMT against the ancestral virus is only 21.73, an accurate fold-reduction in neutralizing antibody titer cannot be determined.
Takeaway is that mRNA vaccines are very immunogenic in general. Hard to say if a more immunogenic coronavac would fare well against omicron or not.
Scoundreller|4 years ago
Relevantly, it looked at omicron.
A few points:
> Third, we have not assessed the T cell immunity against the Omicron variant, which correlates with disease severity.
Non-antibody immune response is understudied. I suspect antibodies are just easy to measure, but, unfortunately for my academic record, there’s more to immune responses than just antibodies.
> Fourth, since all Coronavac recipients had an MN titer of <10 against the Omicron variant and the GMT against the ancestral virus is only 21.73, an accurate fold-reduction in neutralizing antibody titer cannot be determined.
Takeaway is that mRNA vaccines are very immunogenic in general. Hard to say if a more immunogenic coronavac would fare well against omicron or not.